Page header

Recommendation of the President – Nubeqa (darolutamide)

On 23 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 55/2026 on the inclusion of the medicinal product Nubeqa (darolutamide) in the reimbursement program B.56 “Treatment of patients with prostate cancer (ICD-10: C61)”

Publication in Public Information Bulletin (BIP) >>